The U.S. Food and Drug Administration continues to facilitate the development and availability of innovative medical products, such as regenerative medicine therapies, that have the potential to treat or even cure diseases or conditions for which few effective treatment options exist.
Regenerative medicine aspires to transform the future practice of medicine by providing curative, rather than palliative, treatments. Healing the central nervous system (CNS) remains among regenerative medicine’s most highly prized but formidable challenges.
Researchers believe they're getting closer to getting approved stem cell treatments on the market, but it takes time.
The regulatory principles that apply for the clinical development of conventional therapies also apply to regenerative medicines.
Researchers at the National Institutes of Health have devised a four-part small-molecule cocktail that can protect stem cells called induced pluripotent stem cells (iPSCs) from stress and maintain normal stem cell structure and function.
Source: PR Newswire
Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTC: ORTIF) ("Ortho RTI" or the "Company"), a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies
Source: News Medical Life Sciences
Researchers at the University of Southampton have developed a new way of using nanomaterials to identify and enrich skeletal stem cells - a discovery which could eventually lead to new treatments for major bone fractures and the repair of lost or damaged bone.